BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9808534)

  • 21. A possible role for metalloproteinases in renal cyst development.
    Obermüller N; Morente N; Kränzlin B; Gretz N; Witzgall R
    Am J Physiol Renal Physiol; 2001 Mar; 280(3):F540-50. PubMed ID: 11181417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis.
    Nemeth JA; Yousif R; Herzog M; Che M; Upadhyay J; Shekarriz B; Bhagat S; Mullins C; Fridman R; Cher ML
    J Natl Cancer Inst; 2002 Jan; 94(1):17-25. PubMed ID: 11773278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-alpha receptors in a human colon adenocarcinoma (Colo 205) cell line.
    Lombard MA; Wallace TL; Kubicek MF; Petzold GL; Mitchell MA; Hendges SK; Wilks JW
    Cancer Res; 1998 Sep; 58(17):4001-7. PubMed ID: 9731514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of batimastat, a synthetic inhibitor of matrix metalloproteinases, in neutralizing local tissue damage induced by BaP1, a hemorrhagic metalloproteinase from the venom of the snake bothrops asper.
    Escalante T; Franceschi A; Rucavado A; Gutiérrez JM
    Biochem Pharmacol; 2000 Jul; 60(2):269-74. PubMed ID: 10825472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of bleomycin-induced pulmonary fibrosis in mice by the matrix metalloproteinase inhibitor batimastat.
    Corbel M; Caulet-Maugendre S; Germain N; Molet S; Lagente V; Boichot E
    J Pathol; 2001 Apr; 193(4):538-45. PubMed ID: 11276015
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Matrix metalloproteinase inhibition facilitates cell death in intracerebral hemorrhage in mouse.
    Grossetete M; Rosenberg GA
    J Cereb Blood Flow Metab; 2008 Apr; 28(4):752-63. PubMed ID: 17971790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.
    Prontera C; Mariani B; Rossi C; Poggi A; Rotilio D
    Int J Cancer; 1999 May; 81(5):761-6. PubMed ID: 10328230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2.
    Sato H; Kinoshita T; Takino T; Nakayama K; Seiki M
    FEBS Lett; 1996 Sep; 393(1):101-4. PubMed ID: 8804434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer.
    Wojtowicz-Praga S; Low J; Marshall J; Ness E; Dickson R; Barter J; Sale M; McCann P; Moore J; Cole A; Hawkins MJ
    Invest New Drugs; 1996; 14(2):193-202. PubMed ID: 8913840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The metalloproteinase inhibitor batimastat (BB-94) causes cell cycle phase perturbations in ovarian cancer cells.
    Erba E; Ronzoni S; Bassano L; Giavazzi R; D'Incalci M
    Ann Oncol; 1999 May; 10(5):589-91. PubMed ID: 10416010
    [No Abstract]   [Full Text] [Related]  

  • 31. Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice.
    Winding B; NicAmhlaoibh R; Misander H; Høegh-Andersen P; Andersen TL; Holst-Hansen C; Heegaard AM; Foged NT; Brünner N; Delaissé JM
    Clin Cancer Res; 2002 Jun; 8(6):1932-9. PubMed ID: 12060638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
    Sakata K; Shigemasa K; Nagai N; Ohama K
    Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of matrix metalloproteinase inhibitors in cancer therapy.
    Hidalgo M; Eckhardt SG
    J Natl Cancer Inst; 2001 Feb; 93(3):178-93. PubMed ID: 11158186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of airway remodeling-associated mediators by the antifibrotic compound, pirfenidone, and the matrix metalloproteinase inhibitor, batimastat, during acute lung injury in mice.
    Corbel M; Lanchou J; Germain N; Malledant Y; Boichot E; Lagente V
    Eur J Pharmacol; 2001 Aug; 426(1-2):113-21. PubMed ID: 11525779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of matrix metalloproteinases and effect of MMP-inhibition in heart transplant related reperfusion injury.
    Falk V; Soccal PM; Grünenfelder J; Hoyt G; Walther T; Robbins RC
    Eur J Cardiothorac Surg; 2002 Jul; 22(1):53-8. PubMed ID: 12103373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Membrane type 1-matrix metalloproteinase is involved in the formation of hepatocyte growth factor/scatter factor-induced branching tubules in madin-darby canine kidney epithelial cells.
    Kadono Y; Shibahara K; Namiki M; Watanabe Y; Seiki M; Sato H
    Biochem Biophys Res Commun; 1998 Oct; 251(3):681-7. PubMed ID: 9790969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Front-cell-specific expression of membrane-type 1 matrix metalloproteinase and gelatinase A during cohort migration of colon carcinoma cells induced by hepatocyte growth factor/scatter factor.
    Nabeshima K; Inoue T; Shimao Y; Okada Y; Itoh Y; Seiki M; Koono M
    Cancer Res; 2000 Jul; 60(13):3364-9. PubMed ID: 10910039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation of the sphingomyelin/ceramide pathway and smooth muscle cell proliferation.
    Augé N; Maupas-Schwalm F; Elbaz M; Thiers JC; Waysbort A; Itohara S; Krell HW; Salvayre R; Nègre-Salvayre A
    Circulation; 2004 Aug; 110(5):571-8. PubMed ID: 15277330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat.
    Rasmussen HS; McCann PP
    Pharmacol Ther; 1997; 75(1):69-75. PubMed ID: 9364582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Matrix metalloproteinases and atherosclerosis. Therapeutic aspects].
    Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
    Ann Biol Clin (Paris); 2003; 61(2):147-58. PubMed ID: 12702469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.